Market analysts think Allergan needs to strike a deal as Botox biosimilar announced

Mylan and Revance Therapeutics announced plans to develop and commercialize a biosimilar to Allergan's Botox, TheStreet reports.

Here's what you should know.

1. Market analysts believe the deal puts pressure on Allergan to announce a significant deal to counteract the biosimilar announcement.

2. Mizuho Securities analyst Irina Koffler said, "We think Allergan [management] must now prepare for the prospect of a viable global biosimilar and make preemptive plans to diversify its business into other verticals rather than focus primarily on its international cosmetic build-out."

3. Allergan is in the midst of acquiring Elastagen Pty, an injectable aesthetics product development company, but Allergan's President and CEO Brent Saunders said 2018 "will be a relatively boring year for Allergan on the [acquisition] front."

4. The Mylan announcement sent Allergan's stock into a slump. The company's stock lost 3.8 percent in value March 1. In 2018, Allergan's stock has declined 9.3 percent to date.

More articles on supply chain:
Physicians Endoscopy supports Colon Cancer Awareness Month: 5 things to know
HSA PrimeCare opens complex with surgery center — 4 facts
Net revenue by specialty for ASCs in the Midwest — 10 statistics

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months